Home | Published Research | Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

November 30, 2020

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

Written By

Landovitz RJ, Li S, Eron JJ, Jr., Grinsztejn B, Dawood H, Liu AY, et al.